Condition
Antibody-drug Conjugates
Total Trials
6
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (3)
Trial Status
Recruiting3
Not Yet Recruiting2
Unknown1
Clinical Trials (6)
Showing 6 of 6 trials
NCT07355764Phase 2Not Yet Recruiting
MA-CRC-II-016 SHR-1811
NCT07309770Phase 2Recruiting
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
NCT07164950Not ApplicableRecruiting
Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients
NCT07168083Not Yet Recruiting
Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression
NCT06877416RecruitingPrimary
Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
NCT05979740Phase 2Unknown
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC
Showing all 6 trials